VistaGen Therapeutics's total assets for Q3 2026 were $65.06M, a decrease of -19.61% from the previous quarter. VTGN total liabilities were $14.14M for the fiscal quarter, a -3.11% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.